In a Phase I study (NCT03545815), it was shown that the combined administration of MSLN CAR-T, together with programmed cell death protein 1 (PD-1) blockade, strongly increased the cytotoxicity and persistence of T cells within the tumor [98,99]. The gene discussed is PDCD1; the disease is neoplasm.